Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back of ordinary fully paid shares. The company reported that, as of 11 March 2026, it has repurchased a cumulative 5,607,148 shares, including 83,395 shares bought back on the previous trading day.
The update, which follows the initial buy-back notification lodged on 23 October 2025, confirms the continued execution of the capital management program. This sustained on-market repurchase reduces the company’s free float and may enhance earnings per share, signalling management’s confidence in the business and potentially supporting shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian pathology services provider listed on the ASX under the code ACL. The company operates clinical laboratories and offers diagnostic testing services, supplying routine and specialist pathology solutions to healthcare providers across its domestic market.
Average Trading Volume: 704,995
Technical Sentiment Signal: Sell
Current Market Cap: A$419M
Learn more about ACL stock on TipRanks’ Stock Analysis page.